2. Search Result
Search Result
Results for "

targets CD79b

" in MedChemExpress (MCE) Product Catalog:

5

Inhibitors & Agonists

2

Fluorescent Dye

3

Inhibitory Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99042
    Polatuzumab
    2 Publications Verification

    		 Transmembrane Glycoprotein ADC Antibody Cancer
    Polatuzumab is a monoclonal antibody that targets CD79b on the surface of B cells. Polatuzumab can be used to synthesize the ADC Polatuzumab Vedotin (HY-132253), which has anti-tumor activity .
    Polatuzumab
  • HY-132253
    Polatuzumab vedotin

    		Antibody-Drug Conjugates (ADCs) Transmembrane Glycoprotein Cancer
    Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. The antibody portion is Polatuzumab (HY-P99042), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL) .
    Polatuzumab vedotin
  • HY-132253A
    Polatuzumab vedotin (solution)

    		Antibody-Drug Conjugates (ADCs) Transmembrane Glycoprotein Cancer
    Polatuzumab vedotin solution is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. The antibody portion is Polatuzumab (HY-P99042), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Polatuzumab vedotin solution has the potential for the research of Large B-cell lymphomas (LBCL) .
    Polatuzumab vedotin (solution)
  • HY-157763
    Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1

    		PROTAC-Linker Conjugates for PAC Transmembrane Glycoprotein Cancer
    Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1 (Compound 3) is a "linker-payload" component of an antibody-drug conjugate (ADC). Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1 selectively delivers the dual-function BTK degrader to B-cell malignancies by targeting the monoclonal antibody of CD79b. Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1 can be coupled to the engineered CD79b antibody with cysteine, forming CD79b-3 ADC (ADC linker: (HY-130944); Protac: (HY-163295)).
    Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1
  • HY-P991671
    Anafiltamig

    		CD3 CD20 Transmembrane Glycoprotein Cancer
    Anafiltamig is a trivalent monoclonal antibody inhibitor targeting CD79B, CD3E and MS4A1. Anafiltamig consists of a humanized IgG1κ anti-CD79B arm and a bispecific scFv-based arm targeting CD3E and MS4A1. Anafiltamig simultaneously bridges T and B cells, activating T cells and specifically killing B cell tumors. Anafiltamig can be used for B cell malignancies such as non-Hodgkin lymphoma research .
    Anafiltamig

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: